Drug Trial Radar · NCT02875834
A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia
Last checked: Nov 20, 2026Latest source record: Aug 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
267
Actual
Start
Mar 3, 2017
Primary completion
Feb 14, 2018
Study completion Feb 14, 2018
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 23, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy of two different doses (5 and 10 g) of ZS orally administered once daily (qd) vs placebo in maintaining normokalemia in initially hyperkalemic patients having achieved normokalemia following two days of initial ZS therapy (10g TID).
Conditions
- Hyperkalemia
Interventions
Sodium Zirconium Cyclosilicate (ZS) 10gDrug
Suspension administered 10g orally three times per day, in the first 48-hour of the study for all patients (48-hour open label initial phase)
Sodium Zirconium Cyclosilicate (ZS) 5gDrug
Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
Sodium Zirconium Cyclosilicate (ZS) 10gDrug
Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
PlaceboDrug
Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Least Square Mean S-K Level on Days 8-29Time frame: Through 28-day randomized treatment study phase day 8-29.
Locations
45 sites in 4 countries. Site status is shown where the registry gives one.
Research Site
Chiba, Japan
Research Site
Hanyu-shi, Japan
Research Site
Hitachi-Naka, Japan
Research Site
Ina-shi, Japan
Research Site
Kanazawa, Japan
Research Site
Koga-shi, Japan
Research Site
Matsudo-shi, Japan
Research Site
Nagoya, Japan
Research Site
Nagoya, Japan
Research Site
Shimajiri-gun, Japan
Research Site
Shizuoka, Japan
Research Site
Toride-shi, Japan
Research Site
Toyohashi, Japan
Research Site
Yakushi, Japan
Research Site
Krasnoyarsk, Russia
Research Site
Moscow, Russia
Research Site
Saint Petersburg, Russia
Research Site
Saint Petersburg, Russia
Research Site
Yaroslavl, Russia
Research Site
Yekaterinburg, Russia
Research Site
Anyang-si, South Korea
Research Site
Bucheon-si, South Korea
Research Site
Bucheon-si, South Korea
Research Site
Busan, South Korea
Research Site
Cheongju-si, South Korea
Research Site
Goyang-si, South Korea
Research Site
Goyang-si, South Korea
Research Site
Gwangju, South Korea
Research Site
Hwaseong-si, South Korea
Research Site
Incheon, South Korea
Research Site
Incheon, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Suwon, South Korea
Research Site
Uijeongbu-si, South Korea
Research Site
Wŏnju, South Korea
Research Site
Hualien City, Taiwan
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.